This page is intended for UK healthcare professionals and other relevant decision makers only. If you are a member of the public, please click here.
This portal is funded and owned by Novartis Pharmaceuticals UK Ltd and includes content approved by Novartis.
Adverse events reporting information can be found in the footer of this page.
Cosentyx® (secukinumab) is indicated for the treatment of moderate to severe plaque psoriasis (PsO) in adults, children and adolescents from the age of 6 years who are candidates for systemic therapy; active psoriatic arthritis (PsA) in adult patients (alone or in combination with methotrexate [MTX]) when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate; active moderate to severe hidradenitis suppurativa (HS; acne inversa) in adults with an inadequate response to conventional systemic HS therapy.1,2
Cosentyx is intended for use under the guidance and supervision of a physician experienced in the diagnosis and treatment of conditions for which Cosentyx is indicated.
This page contains a 5-minute video demonstrating how to prepare and deliver Cosentyx with the UnoReady® pen.
For a 300 mg dose, one 300 mg pen or two 150 mg pens are needed.
For information on the Cosentyx SensoReady® 150 mg pen click here.
VIDEO
This video has been funded and developed by Novartis Pharmaceuticals UK Ltd.
Do not share screenshots or links to this website, video with patients, as this website is intended for healthcare professionals only. If you do wish to share a video with patients who have been prescribed Cosentyx, please share this link:
Click here for Cosentyx (secukinumab) prescribing information
Therapeutic indications1,2
Cosentyx is indicated for the treatment of moderate to severe plaque psoriasis (PsO) in adults, children and adolescents from the age of 6 years who are candidates for systemic therapy; active psoriatic arthritis (PsA) in adult patients (alone or in combination with methotrexate [MTX]) when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate; active ankylosing spondylitis (AS) in adults who have responded inadequately to conventional therapy; active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation as indicated by elevated C-reactive protein and/or magnetic resonance imaging evidence in adults who have responded inadequately to non-steroidal anti-inflammatory drugs; active moderate to severe hidradenitis suppurativa (HS; acne inversa) in adults with an inadequate response to conventional systemic HS therapy; active enthesitis-related arthritis (ERA) in patients 6 years and older (alone or in combination with MTX) whose disease has responded inadequately to, or who cannot tolerate, conventional therapy; active juvenile psoriatic arthritis (JPsA) in patients 6 years and older (alone or in combination with MTX) whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.1,2
AS, ankylosing spondylitis; CRP, C-reactive protein; DMARD, disease-modifying anti-rheumatic drug; ERA, enthesitis-related arthritis; HS, hidradenitis suppurativa; JPsA, juvenile psoriatic arthritis; MRI, magnetic resonance imaging; MTX, methotrexate; nr-axSpA, non-radiographic axial spondyloarthritis; NSAID, non-steroidal anti-inflammatory drug; PsA, psoriatic arthritis; PsO, plaque psoriasis.
References
Cosentyx® (secukinumab) GB Summary of Product Characteristics.
Cosentyx® (secukinumab) NI Summary of Product Characteristics.
UK | October 2024 | FA-11210373
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email [email protected] or call 01276 698370.
